Advertisement

Digestive Diseases and Sciences

, Volume 54, Issue 10, pp 2188–2191 | Cite as

Treatment of HIV-Associated Diarrhea with Curcumin

  • Chris N. ConteasEmail author
  • Abraham M. Panossian
  • Timothy T. Tran
  • Hardeep M. Singh
Original Article

Abstract

Curcumin is the organic extract of turmeric and possesses known anti-inflammatory properties. Our aim was to explore the utility of curcumin in patients with HIV-associated diarrhea. Eight patients with HIV-associated diarrhea were given a mean daily dose of 1,862 mg of curcumin and followed for a mean of 41 weeks. All had resolution of diarrhea and normalization of stool quality in a mean time of 13 ± 9.3 days. Mean number of bowel movements per day dropped from 7 ± 3.6 to 1.7 ± 0.5. Seven of eight patients had considerable weight gain on curcumin (10.8 ± 8.9 lbs). Five of six patients had resolution of bloating and abdominal pain. Patients on anti-retroviral therapy experienced no discernible drug interactions, changes in CD4 count, or changes in HIV viral load while taking curcumin. Curcumin therapy was associated with rapid and complete resolution of diarrhea, substantial weight gain, improvement in the reduction of bloating and abdominal pain.

Keywords

Curcumin HIV Diarrhea Cytokines 

Notes

Acknowledgments

We would like to thank the hospital and Institutional Review Board of Kaiser Permanente Los Angeles Medical Center for approving this investigation.

References

  1. 1.
    Wilcox C, Rabeneck L, Friedman S. AGA technical review: malnutrition and cachexia, chronic diarrhea, and hepatobiliary disease in patients with human immunodeficiency virus infection. Gastroenterology. 1996;111:1724–1752. doi: 10.1016/S0016-5085(96)70040-9.PubMedCrossRefGoogle Scholar
  2. 2.
    Dworkin B, Wormser GP, Rosenthal WS, et al. Gastrointestinal manifestations of the acquired immunodeficiency syndrome: a review of 22 cases. Am J Gastroenterol. 1985;80(10):774–778.PubMedGoogle Scholar
  3. 3.
    Weber R, Ledergerber B, Zbinden R, et al. Enteric infections and diarrhea in human immunodeficiency virus—infected persons: prospective community-based cohort study. Arch Intern Med. 1999;159:1473–1480. doi: 10.1001/archinte.159.13.1473.PubMedCrossRefGoogle Scholar
  4. 4.
    Beaugerie L. HIV enteropathy. Ann Gastroenterol Hepatol (Paris). 1993;29(1):19–23.Google Scholar
  5. 5.
    Stockmann M, Schmitz H, Fromm M, et al. Mechanisms of epithelial barrier impairment in HIV infection. Ann N Y Acad Sci. 2000;915:293–303.PubMedCrossRefGoogle Scholar
  6. 6.
    Bengmark S. Curcumin, an atoxic antioxidant and natural NFkappaB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. J Parent Enter Nutr. 2006;30(1):45–51. doi: 10.1177/014860710603000145.CrossRefGoogle Scholar
  7. 7.
    Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4:1502–1506. doi: 10.1016/j.cgh.2006.08.008.PubMedCrossRefGoogle Scholar
  8. 8.
    Panossian A, Romberg C, McClune A, Singh H, Conteas C. Curcumin for the treatment of IBS: a case series. Gastroenterology. 2007;132(4):371.Google Scholar
  9. 9.
    Cruz-Correa M, Shoskes D, Sanchez P, et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol. 2006;4(8):1035–1038. doi: 10.1016/j.cgh.2006.03.020.PubMedCrossRefGoogle Scholar
  10. 10.
    Guest JL, Ruffin C, Tschampa JM, DeSilva KE. Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir–rotinavir or nelfinavir. Pharmacotherapy. 2004;24(6):727–735. doi: 10.1592/phco.24.8.727.36071.PubMedCrossRefGoogle Scholar
  11. 11.
    Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32(9):920–924. doi: 10.3109/00365529709011203.PubMedCrossRefGoogle Scholar
  12. 12.
    Schmit H, Rokos K, Florian P, et al. Supernatants of HIV-infected immune cells affect the barrier function of human HT-29/B6 intestinal epithelial cells. AIDS. 2002;16(7):983–991.CrossRefGoogle Scholar
  13. 13.
    Reka S, Kotler DP. Intestinal inflammation associated with HIV infection. International Conference on AIDS. vol. 6, June 20–23 1990: 214 (abstract no. Th·B.369).Google Scholar
  14. 14.
    Schmitz H, Fromm M, Bentzel CJ, et al. Tumor necrosis factor-alpha (TNFalpha) regulates the epithelial barrier in the human intestinal cell line HT-29/B6. J Cell Sci. 1999;112:137–146.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Chris N. Conteas
    • 1
    Email author
  • Abraham M. Panossian
    • 1
  • Timothy T. Tran
    • 1
  • Hardeep M. Singh
    • 1
  1. 1.Department of GastroenterologyKaiser Permanente Los Angeles Medical CentreLos AngelesUSA

Personalised recommendations